Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
162.1 USD | +0.84% | -0.31% | +4.68% |
03:43pm | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
09/05 | Medincell: share price rises on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.68% | 28TCr | |
+29.25% | 68TCr | |
+29.16% | 57TCr | |
-3.96% | 36TCr | |
+18.64% | 33TCr | |
+16.02% | 24TCr | |
+9.33% | 21TCr | |
-6.99% | 20TCr | |
+7.84% | 17TCr | |
-1.48% | 16TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Barclays Raises AbbVie Price Target to $175 From $170, Maintains Overweight Rating